Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IVA
IVA logo

IVA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Inventiva SA (IVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.560
1 Day change
16.92%
52 Week Range
7.980
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Inventiva SA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has short-term upside momentum, but the longer-term technical picture is still bearish, there are no fresh news catalysts, and financial details are unavailable, making this a speculative entry rather than a clean long-term purchase. If the goal is to invest now without waiting for a perfect entry, this is still better treated as a hold than an immediate buy.

Technical Analysis

IVA closed at 3.98, up 5.96% on the day, which shows strong near-term momentum. MACD is positive and expanding, supporting the current bounce. RSI_6 at 64.269 is neutral-to-bullish but not overbought. However, the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, which means the broader trend is still down. Price is now near R1 at 3.876 and below R2 at 4.021, so it is testing resistance rather than breaking into a confirmed uptrend. The model-based trend estimate is mixed to slightly weak over the next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Option sentiment is extremely bullish on paper, with put-call ratios at 0.0 for both open interest and volume, indicating almost no bearish positioning. Call open interest is 40,566 versus just 14 puts, and option activity is far above the 30-day average. That said, implied volatility is extremely elevated at 749.35, with IV rank 96.11 and IV percentile 98.15, showing this is a highly speculative options environment. The options data suggests bullish sentiment, but also very high risk and instability.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
6

Positive Catalysts

  • ["Hedge funds are buying, with buying amount up 681.82% over the last quarter.", "MACD histogram is positive and expanding, showing improving momentum.", "Strong day gain of 5.96% suggests buyers are active now.", "Options positioning is heavily call-skewed with zero put-call ratio, indicating bullish sentiment.", "No negative news in the recent week."]

Neutral/Negative Catalysts

  • ["No news catalysts in the last week.", "Longer-term technical trend is still bearish as SMA_200 > SMA_20 > SMA_5.", "No recent congress trading data.", "Insiders are neutral with no meaningful buying signal.", "Implied volatility is extremely high, which signals a speculative trading environment.", "Model trend estimate turns negative over the next month."]

Financial Performance

No financial snapshot was available due to a data error, so the latest quarter financial performance cannot be assessed. Because the latest quarter season is not provided, there is no confirmed revenue or earnings growth readout to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no visible recent shift in Wall Street sentiment to report. Based on the available data, the Wall Street pros view is limited because there is no clear confirmation from analysts, while the cons view is stronger due to the bearish long-term chart structure and lack of fundamental visibility.

Wall Street analysts forecast IVA stock price to rise
6 Analyst Rating
Wall Street analysts forecast IVA stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.900
sliders
Low
11
Averages
15.67
High
26
Current: 3.900
sliders
Low
11
Averages
15.67
High
26
Stifel
Buy
downgrade
$17 -> $15
AI Analysis
2026-03-31
Reason
Stifel
Price Target
$17 -> $15
AI Analysis
2026-03-31
downgrade
Buy
Reason
Stifel lowered the firm's price target on Inventiva to $15 from $17 and keeps a Buy rating on the shares. The firm notes the company is in final stretches of its pivotal NATiV3 of lanifibranor/Lani in MASH, which reads out in Q4 2026. Expectations for this trial success are high given the strong powering, longer duration trial, and the well-screened population, Stifel adds. In parallel, Inventiva is establishing the Lani profile for its ability to address the underlying metabolic dysfunction related to liver disease - making it ideally suited for the T2D MASH population. Though the market is served by Rezdiffra and Wegovy, Stifel believes Lani can find clear positioning within this commercial offering.
Truist
initiated
$13
2026-03-18
Reason
Truist
Price Target
$13
2026-03-18
initiated
Reason
Truist initiated coverage of Inventiva with a Buy rating and $13 price target. Lead asset lanifibranor has a unique mechanism and profile among metabolic dysfunction-associated steatohepatitis therapies in development that could make it "an ideal choice" for a niche group of MASH patients with diabetes, the analyst tells investors. Near-term Phase 3 data due in the second half of the year "could result in up to +100% upside from current levels," contends the analyst, who estimates base case third-line use in MASH F2/F3 supports $2.3B worldwide peak adjusted revenue.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IVA
Unlock Now

People Also Watch